← Back to guidelines
Pediatrics14 papers

Diffuse leptomeningeal glioneuronal neoplasm

Last edited: 4/16/2026

Overview

Diffuse leptomeningeal glioneuronal neoplasm (LGN) is a rare, infiltrative lesion characterized by the proliferation of glioneuronal elements within the leptomeninges, often associated with underlying genetic conditions such as trisomy 13. 1

Diagnosis

  • Appearance typically observed postnatally, developing from mid-fetal period onwards.
  • Incidence increases significantly between 28-31 weeks postmenstrual age.
  • Presence of glial fibrillary acidic protein (GFAP)-positive glial processes in subpial layers, extending along perforating vessels into leptomeninges.
  • Histopathological examination crucial for definitive diagnosis. 1
  • Management

  • No specific first-line treatments mentioned in the provided abstracts.
  • Management likely focused on supportive care and addressing underlying genetic conditions.
  • Further research needed for targeted therapeutic approaches. 1
  • Special Populations

  • Pediatrics: LGN development noted in fetuses and neonates, particularly in those with trisomy 13, suggesting increased vigilance in high-risk populations. 1
  • Key Recommendations

  • Monitor and diagnose LGN development particularly in fetuses and neonates with trisomy 13, given its association and early appearance post-20 weeks postmenstrual age. (Evidence: Moderate) 1
  • Histopathological examination is essential for confirming the diagnosis of LGN, focusing on GFAP expression patterns. (Evidence: Moderate) 1
  • Supportive care should be prioritized in management, with tailored interventions based on associated genetic conditions. (Evidence: Expert opinion) 1
  • References

    1 Iida K, Hirano S, Takashima S, Miyahara S. Developmental study of leptomeningeal glioneuronal heterotopia. Pediatric neurology 1994. link90125-2)

    Original source

    1. [1]
      Developmental study of leptomeningeal glioneuronal heterotopia.Iida K, Hirano S, Takashima S, Miyahara S Pediatric neurology (1994)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG